These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prognostic value of plasma myeloperoxidase in ESRD patients.
    Author: Wang AY, Lam CW, Chan IH, Wang M, Lui SF, Sanderson JE.
    Journal: Am J Kidney Dis; 2010 Nov; 56(5):937-46. PubMed ID: 20638167.
    Abstract:
    BACKGROUND: Myeloperoxidase (MPO) has been suggested to have a role in atherosclerosis through its strong oxidative capacity. We hypothesized that MPO level may predict clinical outcomes in patients with end-stage renal disease receiving long-term peritoneal dialysis (PD) therapy. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 236 long-term PD patients were recruited from a single regional dialysis unit in Hong Kong between April 1999 and February 2001. PREDICTOR: Level of plasma MPO, analyzed using a sandwich enzyme-linked immunosorbent assay. OUTCOME & MEASUREMENT: Mortality and fatal or nonfatal cardiovascular events at 3 years. RESULTS: The distribution of MPO levels was skewed with a median of 31.8 μg/L (25th-75th percentiles, 24.4-42.7). There were 69 deaths and 81 cardiovascular events. Adjusting for traditional and nontraditional risk factors and C-reactive protein, cardiac troponin T, and N-terminal pro-brain natriuretic peptide levels, a doubling in plasma MPO level was associated independently with a 46% (95% CI, 1.02-2.08; P = 0.04) and 60% (95% CI, 1.17-2.18; P = 0.003) increase in risks of mortality and cardiovascular events, respectively. Log(2)MPO showed significant additional predictive value for mortality (P = 0.04) and cardiovascular events (P = 0.005) when included in Cox regression models consisting of clinical, demographic, dialysis, echocardiographic, and biochemical parameters, as well as C-reactive protein, cardiac troponin T, and N-terminal pro-brain natriuretic peptide levels. LIMITATIONS: MPO was measured at a single time and did not reflect changes over time. CONCLUSIONS: These data suggest that plasma MPO level has significant independent and additional prognostic value beyond the standard clinical, biochemical, and echocardiographic parameters and is useful for outcome stratification in long-term PD patients. MPO may be an important mediator of increased cardiovascular risk in patients with end-stage renal disease and warrants further investigation.
    [Abstract] [Full Text] [Related] [New Search]